TD Cowen analyst Joseph Thome downgraded Marinus Pharmaceuticals (MRNS) to Hold from Buy without a price target after the Phase III trial of ganaxolone in tuberous sclerosis complex failed to meet the primary endpoint. The firm cites the company’s given cash constraints and unclear timing on next steps for the downgrade.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies
- Marinus Pharmaceuticals price target lowered to $3 from $23 at EF Hutton
- Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird
- Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities
- Marinus downgraded to Market Perform from Outperform at JMP Securities
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue